Abstract:Gastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal tract. Surgery is the standard treatment for localised disease, but the risk of relapse and progression to more advanced disease is substantial. Following the discovery of the molecular mechanisms underlying GISTs, targeted therapies for advanced GIST were developed, with the first being the tyrosine kinase inhibitor (TKI) imatinib. Imatinib is recommended in international guidelines as first-line therapy to reduce the risk of GIST relapse in high-risk patients, and for locally advanced, inoperable and metastatic disease. Unfortunately, imatinib resistance frequently occurs and, therefore, second-line (sunitinib) and third-line (regorafenib) TKIs have been developed. Treatment options are limited for patients with GIST that has progressed despite these therapies. A number of other TKIs for advanced/metastatic GIST have been approved in some countries. Ripretinib is approved as fourth-line treatment of GIST and avapritinib is approved for GIST harbouring specific genetic mutations, while larotrectinib and entrectinib are approved for solid tumours (including GIST) with specific genetic mutations. In Japan, pimitespib, a heat shock protein 90 (HSP90) inhibitor, is now available as a fourth-line therapy for GIST. Clinical studies of pimitespib have indicated that it has good efficacy and tolerability, importantly not displaying the ocular toxicity of previously developed HSP90 inhibitors. Additional approaches for advanced GIST have been investigated, including alternative uses of currently available TKIs (such as combination therapy), novel TKIs, antibody-drug conjugates, and immunotherapies. Given the poor prognosis of advanced GIST, the development of new therapies remains an important goal.

Advance on the research and clinical treatment of gastrointestinal stromal tumors

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

[Treatment Progress of Gastrointestinal Stromal Tumor].

New Developments in Gastrointestinal Stromal Tumor

Standardized Treatment of Gastrointestinal Stromal Tumors

Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors

Some Hot Spots in the Treatment of Gastrointestinal Stromal Tumor

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

Diagnosis, Treatment and Prognostic Anlysis on 136 Cases of Gastrointestinal Stromal Tumors

The Pathology, Clinical Diagnosis and Treatment of Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors: Diagnosis and Treatment

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Molecular targeted therapy for the treatment of gastrointestinal stromal tumor

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

Gastrointestinal Stromal Tumors: Current Translational Research and Management Modalities.

[Strategies in Diagnosis and Management for Advanced or Metastatic Gastrointestinal Stromal Tumor].

The Diagnosis and Treatment of Colorectal Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor and Its Adjuvant Therapy

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Advances of endoscopic and surgical management in gastrointestinal stromal tumors

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies